$ 8If SAMI proves out in the "field" and DIMI marches towards a FULL FDA approval ("when not if" per Seto)...
...I stand by my estimate that it will one day be a $ 2B USD asset.
But it will likely need to be in the hands of a major player that can, amoungst other things, leverage their patient clinics into home dialysis (the new paradigm for dialysis)
For example the new JV of Medtronics and DaVita is targeting $ 2B in Sales for home based and innovative care using some unknown hardware. A one times Sales valuation (conservative - but you know me) would be $ 2B USD !
Fresenius a few years back, bought NxStage (and their recently approved FDA machine for home use) for $ 2B USD
Outset had a valuation of close to $ 2B USD a year or so ago (for the then only other dialysis pump approved for home use).
Spectral is potentially sitting on a "game-changing" technology (ease of use, breaks down barriers to adoption in the home, etc.)
Oh and $ 2B USD / 350 M shares = approximately $ 8 /CAD
BUT...Spectral will need a well known partner to drive adoption, sales, etc. So they may have to share some of the upside. I'm OK with that...if it gets the job done and on the path to being worth $ 2B.
MM
PS Morale of the story... don't be stuckupatree and under appreciate the assets that you own